TGFb inducible early gene (TIEG) encodes a three zincfinger Kru¨ppel-like transcription factor whose overexpression has been shown to mimic the effects of TGFb in human osteosarcoma and pancreatic carcinoma cells. In order to investigate a potential role of TIEG in the TGFb signal transduction pathway, we studied its impact on a Smad binding element (SBE) reporter which is known to be regulated by TGFb through the R-Smad proteins. We demonstrate that TIEG overexpression enhances TGFb induction of SBE reporter activity. TIEG overexpression also enhances induction of the endogenous TGFb regulated genes p21 and PAI-1. The ability of TIEG to enhance TGFb actions is Smad dependent since TIEG has no effect on SBE transcription in the absence of Smad4 expression or when an inhibitory Smad protein, Smad7, is overexpressed. Furthermore, TIEG overexpression enhances TGFb induced Smad2 phosphorylation. Lastly, TIEG appears to function by binding to and thereby repressing a specific element in the proximal promoter of the inhibitory Smad7 gene. In conclusion, these results describe a novel mechanism for the potentiation of TGFb/Smad signaling via repression of the inhibitory Smad7 gene by TIEG.
TGFb inducible early gene (TIEG) encodes a three zincfinger Kru¨ppel-like transcription factor whose overexpression has been shown to mimic the effects of TGFb in human osteosarcoma and pancreatic carcinoma cells. In order to investigate a potential role of TIEG in the TGFb signal transduction pathway, we studied its impact on a Smad binding element (SBE) reporter which is known to be regulated by TGFb through the R-Smad proteins. We demonstrate that TIEG overexpression enhances TGFb induction of SBE reporter activity. TIEG overexpression also enhances induction of the endogenous TGFb regulated genes p21 and PAI-1. The ability of TIEG to enhance TGFb actions is Smad dependent since TIEG has no effect on SBE transcription in the absence of Smad4 expression or when an inhibitory Smad protein, Smad7, is overexpressed. Furthermore, TIEG overexpression enhances TGFb induced Smad2 phosphorylation. Lastly, TIEG appears to function by binding to and thereby repressing a specific element in the proximal promoter of the inhibitory Smad7 gene. In conclusion, these results describe a novel mechanism for the potentiation of TGFb/Smad signaling via repression of the inhibitory Smad7 gene by TIEG. Oncogene (2002 Oncogene ( ) 21, 5783 -5790. doi:10.1038 Keywords: Smad; TGFb; TIEG; transcription; zincfinger The members of the transforming growth factor-b (TGFb) superfamily, including bone morphogenetic proteins (BMPs) and the TGFbs, serve critical roles in cellular differentiation, apoptosis, migration, and control of proliferation. In addition, insensitivity to the growth-inhibitory effect of TGFb plays an important role in many types of cancer including pancreatic, colorectal, lung, breast and ovarian cancers as well as some head and neck squamous cell carcinomas Kim et al., 1996; Schutte et al., 1996; Takagi et al., 1996) .
TGFb exerts its effects by binding to specific type I and type II serine/threonine kinase receptors, which in turn initiate intracellular signaling via Smad proteins. Ligand binding to the type II receptor induces the formation of a heteromeric complex between specific type II and type I receptors. The type I receptor is then transactivated through phosphorylation by the type II receptor (Derynck and Feng, 1997) . Ligand activated forms of the type I receptor in turn phosphorylate Smad proteins which then translocate to the nucleus and modulate target gene transcription (Miyazono, 2000; ten Dijke et al., 2000) .
The Smad proteins appear to be the primary mediators of TGFb signal transduction. However, in many cell types, other signaling pathways, including the Akt, JNK, p38, and ERK/MAPK pathways, are induced or repressed by TGFb and may be involved in certain TGFb responses (Bakin et al., 2000; Frey and Mulder, 1997; Hanafusa et al., 1999; Hartsough and Mulder, 1995; Hocevar et al., 1999; Imai et al., 1999; Sano et al., 1999) . There are three categories of Smad proteins, the receptor-regulated Smads (R-Smads), common mediator (Co-Smad), and inhibitory Smads (I-Smads). The R-Smads are pathway specific and are directly phosphorylated by their respective type I receptors on a carboxy terminal SSXS motif. Smad2 and 3 function as R-Smads for TGFb and activin signaling, whereas Smad1, 5 and 8 relay signaling in response to BMPs. Upon phosphorylation, R-Smads complex with the Co-Smad, Smad4, translocate to the nucleus and regulate target gene transcription (Miyazono, 2000; ten Dijke et al., 2000) .
The third category of Smad proteins is the I-Smad subfamily, consisting of Smad6 and 7. Smad7 blocks both TGFb and BMP signaling whereas Smad6 preferentially blocks BMP signaling. Smad7 functions in multiple ways by either directly binding the type I receptor and blocking phosphorylation of the RSmads, or by recruiting the ubiquitin ligases, Smurf1 and Smurf2, to the type I receptor and increasing receptor turnover (Ebisawa et al., 2001; Hayashi et al., 1997; Imamura et al., 1997; Kavsak et al., 2000; Nakao et al., 1997) . The Smad7 gene is transcriptionally activated by the R-Smad/Smad4 complex in response to ligand binding and thus serves as a negative feedback loop to TGFb/Smad signaling (Afrakhte et al., 1998) . Therefore, changes in I-Smad expression or activity may likely have a profound impact on the entire TGFb signal transduction system.
TGFb inducible early gene (TIEG) was identified as a transcript that is rapidly induced within 60 min of TGFb treatment in human osteoblasts (Subramaniam et al., 1995) . TIEG is a member of the Kru¨ppel-like factor (KLF) family of three zinc-finger proteins and encodes a 480 amino acid (72 kDa) protein with a unique amino-terminal end distinguishing it from an early growth response-a (EGRa) gene (Blok et al., 1995) . Both proteins are encoded by the same highly conserved gene but are produced from alternative promoters (Fautsch et al., 1998a,b) . Furthermore, EGRa is expressed at much lower levels than TIEG in all tissues (Fautsch et al., 1998b) .
Overexpression of TIEG mimics TGFb activity in many cell types. For example, overexpression of TIEG in MG-63 osteosarcoma cells increases alkaline phosphatase activity, decreases osteocalcin mRNA and protein, and decreases cell proliferation in a manner reminiscent of the effects of TGFb treatment (Hefferan et al., 2000) . In addition, TIEG overexpression induces apoptosis in a manner similar to TGFb treatment in pancreatic, hepatic and lung epithelial cells (Chalaux et al., 1999; Ribeiro et al., 1999; Tachibana et al., 1997) . Finally, TIEG is expressed in a stage-specific manner in a set of breast cancer biopsies. Whereas normal breast tissue displays high levels of TIEG protein, in situ carcinomas display less than one-half the normal TIEG protein levels and invasive carcinomas show no detectable TIEG protein (Subramaniam et al., 1998) . In this study, we have investigated the mechanism by which overexpression of TIEG mimics the actions of TGFb.
Previously, we have reported that the TIEG is an immediate early gene for TGFb in human osteoblasts (Subramaniam et al., 1995) . Using Northern blot analysis, we observed that TIEG mRNA is also rapidly induced by TGFb treatment in AKR2B and Hs578T cells and reaches maximal levels 1 h after treatment (data not shown).
To investigate whether TIEG plays a role in the TGFb and Smad signaling pathways, a TIEG expression construct was transiently transfected into AKR2B cells along with a Smad binding element (SBE) luciferase reporter construct, CAGA 12 -MLP-Luc. Where indicated, a constitutively active type I TGFb receptor (ALK5TD) was cotransfected into the cells to mimic the effects of TGFb treatment (Wieser et al., 1995 and data not shown) . In the absence of TIEG overexpression, ALK5TD induces expression of the Smad binding element reporter construct 3.5-fold ( Figure 1a ). Co-transfection of TIEG with ALK5TD increases induction of reporter gene activity to eightfold while having a minimal effect in the absence of ALK5TD. Similar results were obtained in Mv1Lu, Hep3B, MDA-MB-231, Hs578T and 4T1 cell lines (data not shown). Thus, TIEG enhances TGFb/Smaddependent gene transcription.
In order to determine whether TIEG overexpression enhances induction of endogenous TGFb regulated genes, we utilized a stable doxycycline inducible TIEG overexpressing Hs578T cell line. As shown in Figure  1b , the levels of TIEG protein in these cells are dramatically induced when doxycycline is added to the culture medium. To test the effects of TIEG overexpression on the TGFb induction of endogenous genes, cells were induced to express the TIEG transgene and then treated with TGFb for various time periods. As shown in Figure 1c , the levels of p21 and PAI-1 mRNA increase within 2 h of TGFb treatment in the absence of doxycycline treatment. Pretreatment of cells with doxycycline to induce high levels of TIEG protein ( Figure 1b ) results in an enhanced induction of both transcripts while having a minimal effect on the basal levels of their transcription. In conclusion, TIEG potentiates the induction of endogenous TGFb regulated genes.
The R-Smad proteins are known to be involved in the regulation of both p21 and PAI-1 by TGFb (Dennler et al., 1998; Moustakas and Kardassis, 1998) . Based on our observations that TIEG overexpression is able to enhance only the TGFb-induced activity of the SBE reporter construct as well as of the endogenous p21 and PAI-1 genes, we hypothesized that the influence of TIEG on TGFb induced gene regulation requires the R-Smad proteins. In order to test this hypothesis, the CAGA 12 -MLP-Luc reporter was cotransfected along with various combinations of the inhibitory Smad7, TIEG and ALK5TD. As shown in Figure 2a , Smad7 co-expression abrogates ALK5TD mediated activation in both the presence and absence of TIEG overexpression, suggesting that the increase in activation of the SBE reporter with TIEG coexpression is R-Smad-dependent. In addition, to further test this hypothesis, we transiently transfected the CAGA 12 -MLP-Luc reporter construct with different combinations of ALK5TD, TIEG and a Smad4 expression construct into MDA-MB-468 human breast cancer cells. This cell line has previously been shown to harbor a homozygous deletion in the Smad4 allele, rendering it insensitive to the Smad4 dependent effects of TGFb (de Winter et al., 1997; Schutte et al., 1996) . Accordingly, as shown in Figure 2b , expression of the activated type I receptor, ALK5TD, is unable to induce the CAGA 12 -MLP reporter construct in the absence of exogenous Smad4 expression. Similarly, TIEG is shown to be incapable of activating transcription in the absence of Smad4 whether or not ALK5TD is present. However, cotransfection of Smad4 results in increased basal activity of the reporter construct and restores its responsiveness to ALK5TD. Importantly, TIEG enhances both basal and ALK5TD induced transcription in the presence of Smad4. Thus TIEG mediated enhancement of TGFb induced transcription is Smad4 dependent.
As mentioned previously, TGFb signaling through the Smad pathway is characterized by the phosphorylation of the R-Smads (Smad2 and 3), followed by the subsequent translocation to the nucleus and modula-tion of target gene transcription. In order to investigate the mechanism by which TIEG enhances Smad pathway activity, we tested the effects of TIEG overexpression on Smad2 phosphorylation following TGFb treatment. As shown in Figure 2c , exogenous TGFb treatment increases Smad2 phosphorylation by approximately 20%. Interestingly, simultaneous treatment with TGFb and doxycycline results in a 60% increase in Smad2 phosphorylation. This suggests that TIEG overexpression enhances Smad signaling by increasing the phosphorylation and activation of the R-Smads.
Previous data has indicated that Smad7 serves a negative feedback role to TGFb signaling in other cell types (Afrakhte et al., 1998) . Furthermore, emerging evidence suggests that TIEG is a transcriptional repressor (Cook et al., 1999; Yajima et al., 1997) . Therefore, we hypothesized that the ability of TIEG to enhance R-Smad activation may be due to repression of a Smad signaling inhibitor. Smad7, like TIEG, is an immediate early gene for TGFb in other cell types (Nakao et al., 1997) . As shown in Figure 3a , Smad7 is induced in AKR2B cells with levels sharply increasing following TGFb treatment, suggesting that Smad7 serves as a negative feedback control to TGFb signaling in these cells. The mRNA levels of Smad7 peak at approximately 60 min post TGFb treatment and decline to lower levels thereafter. As with other primary response genes, the levels of Smad7 mRNA remain elevated past 60 min when cells are simultaneously treated with TGFb and cycloheximide, indicating that protein synthesis is required for downregulation of Smad7 transcription (Nakao et al., 1997 and data not shown).
In order to determine whether TIEG regulates endogenous Smad7 expression, a doxycycline inducible TIEG overexpressing Hs578T cell line was used to measure Smad7 mRNA levels following induction of TIEG by doxycycline. As shown in Figure 3b , treatment of cells with doxycycline results in downregulation of endogenous Smad7 mRNA levels. These data suggest that TIEG downregulates endogenous Smad7 gene expression. In addition to blocking basal levels of Smad7 expression, overexpression of TIEG also limits the levels of Smad7 induction following TGFb treatment (Figure 3c ). This reduction of TGFb induced Smad7 mRNA levels directly correlates with the enhanced induction of PAI1 and p21 mRNA levels observed in Figure 1c .
In order to test whether down-regulation of Smad7 is required for TIEG mediated enhancement of TGFb/ Smad signaling, we utilized an RNA interference approach (Elbashir et al., 2001) to attenuate endogenous Smad7 expression. This was performed utilizing double stranded small inhibitory RNA (siRNA) molecules directed against Smad7. As shown in Figure 3d , in the presence of the control siRNA (GL2) TIEG enhances CAGA 12 -MLP-Luc reporter induction by ALK5TD 2.6-fold compared to vector transfected cells. Cotransfection of the Smad7 siRNA reduced the enhancement of reporter gene induction to 1.48-fold, indicating (Dennler et al., 1998) was transfected into AKR2B cells grown in 6-well plates along with the internal control plasmid, pRL-TK (0.5 mg; Promega, Madison, WI, USA), and pcDNA4/TO-Flag-TIEG (1.0 mg) or empty vector, and ALK5TD (0.5 mg) or empty pcDNA3 as indicated using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's directions. Luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega) and samples were read on a Turner TD-20/20 luminometer. To correct for differences in transfection efficiency, firefly luciferase units were normalized relative to renilla luciferase units of the same sample. Corrected luciferase values were then expressed as a ratio (RLU) relative to the vector control transfected cells. Normalized relative values for a representative experiment are shown (n=3). Error bars indicate s.d. (b) Doxycycline inducible Hs578T TIEG overexpressing cells were generated using the T-Rex system (Invitrogen) according to the manufacturer's instructions. These cells were grown in serum-free medium and treated with doxycycline (50 ng/ml) for 24 h where indicated, followed by co-treatment with TGFb 1 (2 ng/ml) for the indicated times. Protein extracts were harvested and analysed by Western blotting using anti-TIEG-228 (Subramaniam et al., 1998) and anti-Actin (AC-40; Sigma, St. Louis, MO, USA) antibodies using standard protocols. (c) Total RNA from duplicate samples in (b) was harvested and analysed by Northern blotting as previously described (Subramaniam et al., 1995) with the indicated probes that the effects of TIEG on Smad signaling are mediated principally through down-regulation of Smad7.
To verify that TIEG inhibits Smad7 gene transcription, a TIEG expression vector was co-transfected with luciferase reporter constructs carrying portions of the mouse and human Smad7 promoters into AKR2B cells. As shown in Figure 4b , TIEG represses the mouse Smad7 promoter activity by 80%. TIEG also represses the human Smad7 promoter by 84%, but has no effect on an unrelated (cyclin D1) promoter (data not shown). Similar results were obtained in Hs578T, MDA-MB-231, SK-BR-3 and Mv1Lu cell lines (data not shown). Initial promoter deletion analysis ( Figure  4a ,b left panel) indicated that repression of the mouse Smad7 promoter by TIEG requires a sequence between nucleotides 7251 and 7126 (Figure 4b left panel) . Since this region contains a GC rich sequence (S7 GC box) identical to the NegB sequence, to which the mouse homolog of TIEG has previously been shown to bind and repress (Yajima et al., 1997) , we performed an additional fine deletion analysis to determine if this element is responsible for TIEG mediated repression of Smad7 promoter activity. Indeed, as shown in Figure  4b (right panel), a construct containing the S7 GC box was repressed by TIEG whereas deletion of this element completely blocks repression by TIEG.
Based on the requirement of the S7 GC box for TIEG-mediated repression and the previous observation that TIEG directly binds the NegB sequence (Yajima et al., 1997) we hypothesized that TIEG may also directly bind the S7 GC box. As shown by electrophoretic mobility shift assay in Figure 4c , TIEG is capable of binding to an oligonucleotide containing this sequence. Furthermore, this binding is specific since TIEG did not bind to a mutant oligonucleotide, and only wild-type and not mutant cold oligonucleotides were able to compete away TIEG binding to the S7 GC box.
In this study we have shown that the overexpression of TIEG enhances the activation of R-Smads and the subsequent induction of TGFb regulated transcription. We propose that TIEG plays a unique role as a component of the TGFb signaling pathway by limiting the duration or magnitude of negative feedback imposed by Smad7. In support of this conclusion, TIEG overexpression down-regulates mRNA levels of the inhibitory Smad7, represses Smad7 promoter activity and binds to a portion of the proximal Smad7 promoter. Furthermore, repression of Smad7 is necessary for TIEG to elicit its effects on TGFb/Smad signaling. In our model, TGFb transcriptionally activates the early response genes TIEG and Smad7 independent of protein synthesis. As Smad7 protein levels begin to rise, TGFb signaling is partially limited by Smad7 binding to the TGFb receptor, thereby blocking phosphorylation of Smad2 and 3. Simultaneously, when Smad7 levels begin to rise, the levels of TIEG also begin to rise. Based on the data presented in this study, newly synthesized TIEG protein would then repress the inhibitory Smad7 gene, re-establish R-Smad phosphorylation and thereby enable activation of later were treated with doxycycline (50 ng/ml) overnight to induce TIEG expression followed by treatment with 2 ng/ml TGFb for 60 min. Protein extracts were harvested and analysed by Western blotting using anti-phospho-Smad2 (Upstate Biotechnology, Lake Placid, NY, USA) and anti-Actin (AC-40) antibodies using standard protocols. Densitometry was performed using ImageQuant software (Molecular Dynamics, Piscataway, NJ, USA) and phospho-Smad2 levels were normalized to Actin and expressed as a percentage increase relative to untreated -Dox, -TGFb) cells TGFb response genes. Further support for this hypothesis is evidenced by the fact that Smad7 mRNA levels, like many primary response genes, remain elevated synthesis upon cycloheximide treatment, suggesting that protein is required for subsequent down-regulation of the Smad7 gene following TGFb induction (Afrakhte et al., 1998) . Our data identify TIEG as one of the candidate proteins involved in down-regulation of the Smad7 gene.
Enhancement of TGFb family member signaling through down-regulation of an inhibitory Smad protein is also supported by recent studies. For instance, the expression of antisense Smad7 RNA enhances induction of the 3TP-lux reporter construct in response to TGFb treatment (Afrakhte et al., 1998) . Furthermore, the sequestering of the inhibitory Smad6 molecule by interaction with AMSH (associated molecule with the SH3 domain of STAM) increases physiological responses to BMP-7, another TGFb superfamily member (Itoh et al., 2001) . Conversely, the up-regulation of inhibitory Smad proteins should result in refraction to TGFb. One such example has been demonstrated in cells isolated from patients with inflammatory bowel disease that express elevated levels of Smad7 in inflamed areas (Monteleone et al., 2001) . Importantly, depletion of Smad7 by anti-sense oligonucleotides restored TGFb responsiveness in these cells. Collectively, these data suggest that modulation of I-Smad levels may often by employed to fine-tune responses to TGFb superfamily members.
Many types of cancer are characterized by resistance to the growth inhibitory effects of TGFb. This has been shown to occur in a number of ways including loss of the TGFb receptors and/or Smad signaling mediators. For example, deletion of the Smad4 gene has been detected in a subset of pancreatic and colon cancers as well as in a few cases of breast and ovarian cancers Kim et al., 1996; Takagi et al., 1996) . Another mechanism by which cells may be able to overcome TGFb mediated growth arrest is by over-expressing antagonists of Smad signaling such as the I-Smads, c-Ski or SnoN (Kleeff et al., 1999a,b; Luo et al., 1999; . Overexpression of Smad6 and 7 has been observed in pancreatic cancer (Kleeff et al., 1999a,b) and overexpression of v-Ski (Colmenares and Stavnezer, 1989) or SnoN (Boyer et al., 1993) induces the malignant transformation of chicken fibroblasts. Furthermore, overexpression of Smad7 in COLO-357 pancreatic cells leads to a complete loss of TGFb induced growth arrest as well as increased tumor mass in nude mice (Kleeff et al., 1999b) . Thus, overexpression of Smad7 may provide another mechanism for TGFb insensitivity in certain cell types as a distinct mechanism from mutations in the TGFb receptors, Smad4 or the R-Smads.
We hypothesize that loss of TIEG expression could potentially lead to elevated levels of Smad7 thereby resulting in a complete or partial blockage of the TGFb/Smad signaling pathway and a loss of cell cycle control involving the TGFb tumor suppressor path- way. Although the expression levels of Smad7 protein and mRNA have not yet been investigated in breast cancer biopsies, our laboratory previously reported that the decrease in the expression levels of TIEG Figure 4 (a) Smad7 promoter deletion constructs were generated by restriction digests or PCR of the mouse Smad7 promoter (Nagarajan et al., 1999) followed by cloning into pGL3-Basic (Promega). (b) Smad7 promoter deletion constructs (500 ng) shown in a were transfected into AKR2B cells along with the internal control plasmid, pRL-TK (250 ng), and pcDNA4/TO-Flag-TIEG (500 ng) or empty vector as indicated. (c) Electrophoretic mobility shift assay was performed as previously described (Zhang et al., 2000) using baculovirus expressed and purified His-tagged TIEG protein. Oligonucleotides used were: S7 GC sense, 5'-AGG-TATGGGGGCGGGGGA-3'; S7 GC antisense, 5'-TGGTATCCCCCGCCCCCA-3'; S7 GC Mut sense, 5'-AGG-TATTGTTGCGGGGTA-3'; S7 GC Mut antisense, 5'-TGGTATACCCCGCAACAA-3'. The underlined sequences denote the GC box. The left panel shows the specificity of TIEG binding to the GC box in the Smad7 promoter as determined by competition with unlabeled (cold) oligonucleotides. The right panel identifies the shifted complex as containing the TIEG. The arrows indicate the shift (S) and super-shifted (SS) complexes, a-228 indicates the addition of the anti-TIEG antibody to the binding reaction, PI indicates the addition of pre-immune serum to the binding reaction protein correlates with the advancing stage of breast cancer biopsies (Subramaniam et al., 1998) . Future studies are planned to examine whether the expression levels of TIEG and Smad7 in breast cancers are inversely correlated.
